Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a faster pacemaker setting boost heart and brain health?

NCT ID NCT07589452

Disease control Sponsor: Medtronic Cardiac Rhythm and Heart Failure Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 21, 2026 · Updated 2 times

Summary

This study looks at whether setting a pacemaker to a personalized rate of 75 beats per minute, instead of the usual 50-60, can improve heart function and blood flow to the brain in people with high blood pressure and a slow heart rate. About 70 patients aged 65 and older will be randomly assigned to either the personalized rate or standard rate. Researchers will measure changes in heart function and brain blood flow after 3 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pacemaker with personalized lower rate (75 bpm)
What this could lead to
If it works, this could point toward a better way to set pacemakers for hypertensive patients, potentially improving heart and brain function.
What could go wrong
This is a small, early-stage study with only 70 participants, so results may not apply to everyone. The personalized rate may not provide clear benefits over standard settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥65 years of age * Planned implantation of a dual chamber pacemaker with physiological pacing * Resting sinus heart rate ≤60 bpm, or average 24 hour Holter heart rate ≤60 bpm * Documented history of hypertension or office systolic blood pressure ≥130 mmHg Exclusion Criteria: * Diagnosis of secondary hypertension * Diagnosis of or possible concomitant heart failure, with ejection fraction ≤50% * Paroxysmal, persistent, or permanent atrial fibrillation * Status post CABG or PCI * Structural heart disease * Risk of ventricular tachyarrhythmia * Severe hepatic or renal dysfunction * Active acute infection * Inability to sign informed consent * Pregnancy or planned pregnancy during the study period * Enrollment in other clinical studies that may affect the objectives of this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bradycardia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bradycardia hypertensive disorder sick sinus syndrome sinoatrial node disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bradycardia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanxi Cardiovascular Hospital

    RECRUITING

    Taiyuan, Shanxi, 030024, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.